Left ventricular hypertrophy in hypertensive type 2 diabetic patients according to renal function

AimCardiovascular disease is the main cause of death in diabetic patients undergoing haemodialysis. Dialysis and hypertension increase left ventricular hypertrophy (LVH), a strong predictor of cardiovascular events. This study evaluated left ventricular structure and function in three groups of hypertensive type 2 diabetic patients with different renal function, and assessed the factors associated with LVH, in an Afro-Caribbean population.MethodsLeft ventricular structure and function were measured by ultrasonography. Group 1 consisted of 150 patients with normal renal function, group 2 included 183 patients with renal dysfunction and the third group comprised 75 dialysis patients.ResultsLeft ventricular mass/height^2.7 increased from group 1 to groups 2 and 3 (49.00 g/m^2.7, 57.12 g/m^2.7 and 59.75 g/m^2.7, respectively; P < 0.0001). The prevalences of LVH were 48.3% in group 1, 64.8% in group 2 and 70.3% in the dialysis patients (P = 0.001). LVH was more concentric than eccentric in groups 2 and 3.The factors significantly associated with LVH were obesity in groups 1 and 2, and an increase of 10 mmHg in pulse pressure in groups 2 and 3, according to multivariate logistic-regression analysis.ConclusionOur study confirmed that, in a population of Afro-Caribbean hypertensive type 2 diabetic patients, renal failure was associated to an increased left ventricular mass/height^2.7. The data show that the variables associated with LVH differ according to renal profile. This finding will be of value in the treatment and follow-up of these patients.     

Type 2 diabetes is associated with left ventricular concentric remodeling in hypertensive patients

BACKGROUND: Left ventricular (LV) geometric remodeling is associated with cardiovascular prognosis in hypertensive patients. It is uncertain how LV remodeling is modulated by diabetes in hypertensive patients. In this study, we investigated the impact of diabetes and ambulatory blood pressure (BP) on LV geometric remodeling in hyptensives with/without diabetes. METHODS: Ambulatory BP monitoring and echocardiography were performed to compare 24-h BP levels and LV measurements in 400 uncomplicated hypertensives (mean age, 67 years, 152 men and 248 women) between diabetic (n = 161) and nondiabetic (n = 239) patients. RESULTS: The age (67 v 68 years), percentage of men (43% v 34%), body mass index (24.5 v 24.0 kg/m(2)), 24-h systolic BP (144/80 v 144/82 mm Hg), LV mass index (128 v 130 g/m(2)) were similar between the groups. Diabetic patients had higher relative wall thickness (0.50 v 0.44, P < .001) and higher prevalence of concentric LV hypertrophy (39.4% v 26.8%, P < .001) than nondiabetic patients. The presence of diabetes (odds ratio [OR] = 2.76; 95% confidence interval [CI] = 1.73-4.41, P < .001) and 24-h systolic BP (OR for 10 mm Hg increase = 1.17; 95% CI = 1.01-1.37, P < .05) were independently associated with the higher relative wall thickness (>/=0.45). On the other hand, 24-h systolic BP was independently associated with LV hypertrophy (OR for 10 mm Hg increase = 1.32; 95% CI = 1.14-1.52, P < .05). CONCLUSIONS: Among hypertensive patients, type 2 diabetes was associated with concentric LV geometry independent of ambulatory BP.     

Abnormal regional left ventricular mechanics in treated hypertensive patients with 'normal left ventricular function'

Global systolic and diastolic LV function assessed by conventional echocardiographic indices is often normal in patients with controlled hypertension, with or without left ventricular hypertrophy. However, it is not certain whether regional myocardial function in these patients remains normal. We investigated 26 patients and 10 age matched normal controls, by means of long axis M-mode echocardiography. There was no significant difference in age, sex distribution, heart rate, blood pressure and routine ECG measurements between the two groups. Although there was significant LVH in patients compared to normal controls, LV cavity size and global systolic function, assessed by shortening fraction, ejection fraction and mean velocity of circumferential fibre shortening did not differ between the two groups, nor did LV diastolic function, assessed by the mitral flow pattern. However, LV regional mechanics, as assessed by multiple long axis M-mode echocardiograms differed significantly, in both systole and diastole, between the two groups. Compared to controls, the total longitudinal systolic excursion in both LV free wall and ventricular septum were significantly reduced in patients, and so was maximum early relaxation and atrial contraction in the LV free wall. The mean rate of systolic excursion in all 3 sites did not differ between the two groups, but the mean rate of early relaxation in both LV free wall and ventricular septum was significantly decreased in patients compared to normal controls. In conclusion, the evaluation of LV dysfunction in patients who have achieved good blood pressure control requires more than a conventional echocardiographic assessment. The assessment of regional mechanics described in the present paper offers an easy and sensitive method for the detection of subtle signs of LV mechanical inefficiency associated with LVH.     

Urinary type IV collagen is related to left ventricular diastolic function and brain natriuretic peptide in hypertensive patients with prediabetes

AimUrinary type IV collagen is an early biomarker of diabetic nephropathy. Concomitant prediabetes (the early stage of diabetes) was associated with left ventricular (LV) diastolic dysfunction and increased brain natriuretic peptide (BNP) in hypertensive patients. We hypothesized that urinary type IV collagen may be related to these cardiac dysfunctions.MethodsWe studied hypertensive patients with early prediabetes (HbA1c < 5.7% and fasting glucose > 110, n = 18), those with prediabetes (HbA1c 5.7–6.4, n = 98), and those with diabetes (HbA1c > 6.5 or on diabetes medications, n = 92). The participants underwent echocardiography to assess left atrial volume/body surface area (BSA) and the ratio of early mitral flow velocity to mitral annular velocity (E/e’). Left ventricular diastolic dysfunction (LVDD) was defined if patients had E/e’ ≥ 15, or E/e’ = 9–14 accompanied by left atrial volume/BSA ≥ 32 ml/mm². Urinary samples were collected for type IV collagen and albumin, and blood samples were taken for BNP and HbA1c.ResultsUrinary type IV collagen and albumin increased in parallel with the deterioration of glycemic status. In hypertensive patients with prediabetes, subjects with LVDD had higher levels of BNP and urinary type IV collagen than those without LVDD. In contrast, in hypertensive patients with diabetes, subjects with LVDD had higher urinary albumin and BNP than those without LVDD. Urinary type IV collagen correlated positively with BNP in hypertensive patients with prediabetes, whereas it correlated with HbA1c in those with diabetes.ConclusionsIn hypertensive patients with prediabetes, urinary type IV collagen was associated with LV diastolic dysfunction and BNP.     

Hypertrophic cardiomyopathy is associated with more severe left ventricular dyssynchrony than is hypertensive left ventricular hypertrophy

OBJECTIVE: To evaluate left ventricular (LV) dyssynchrony in patients with left ventricular hypertrophy (LVH), and to compare abnormalities associated with hypertrophic cardiomyopathy (HCM) and hypertensive heart disease (HHD) using 2D speckle tracking imaging. METHODS: Basal, middle, and apical 2D LV short-axis images were acquired in 43 patients with LVH including 20 with HCM and 23 with HHD, and in 15 age-matched controls. Radial strain, circumferential strain, time interval from the R-wave to peak radial strain (Trs), and time to peak circumferential strain (Tcs) were measured in six equidistant segments at each level of the 3 LV short-axis views using 2D speckle tracking analysis. To assess LV dyssynchrony, Trs(cs)-18SD, the standard deviation (SD) of Trs(cs) in all 18 segments, was calculated. RESULTS: Regional radial strain in the middle and apical short-axis segments was significantly less in patients with HCM than in those with HHD. Regional circumferential strain in the apical short-axis segments was also less in HCM. Trs-18SD and Tcs-18SD were significantly longer in patients with HCM than in age-matched controls and patients with HHD (Trs-18SD: HCM: 88 +/- 32 ms, HHD: 51 +/- 20 ms, control: 45 +/- 12 ms P < 0.001, Tcs-18SD: HCM: 71 +/- 27 ms, HHD: 46 +/- 14 ms, control: 45 +/- 14 ms P < 0.001). CONCLUSIONS: The presence of LVH is thus not always associated with LV dyssynchrony. However, the greater reduction of regional strain and severe LV dyssynchrony in HCM may contribute to the adverse cardiovascular outcomes associated with this disease.     

Reduced bone mineral density in hypertensive patients is associated with left ventricular diastolic dysfunction, not left ventricular hypertrophy

Left ventricular (LV) hypertrophy and diastolic dysfunction are commonly observed in hypertensive patients, and have been demonstrated to be risk factors of chronic heart failure due to LV diastolic dysfunction. Recently, reduced bone mineral density has been found in hypertensive patients compared with healthy controls. However, relationships between bone mineral density and LV hypertrophy and diastolic dysfunction have not been fully assessed. We examined relationships between bone mineral density and both LV hypertrophy and diastolic dysfunction in 38 hypertensive patients (23 males, 15 females; mean age 71 ± 8 y) who had been treated with antihypertensive drugs for at least 1 year. The bone mineral density of the calcaneus was measured with a quantitative ultrasound measurement device (A-1000 EXPRESS/InSight, GE Healthcare, Horten, Norway), and the stiffness index was determined as a parameter of bone mineral density. Echocardiography was performed to measure the left ventricular mass index as a parameter of LV hypertrophy. Left ventricular diastolic dysfunction was also assessed by early diastolic mitral annular velocity (e'), and the ratio of early transmitral flow velocity (E) to e' (E/e'). The bone mineral density did not correlate with left ventricular mass index, but did correlate with e' (r = 0.453, P < .01) and E/e' (r = -0.359, P < .05). Thus, reduced bone mineral density in hypertensive patients is not associated with LV hypertrophy but with LV diastolic dysfunction. Hypertensive patients with reduced bone mineral density may have a high risk of chronic heart failure due to LV diastolic dysfunction as well as bone fractures due to osteoporosis.     

Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan

OBJECTIVES: The study was designed to test whether or not the angiotensin II receptor blocker telmisartan brings about regression of left ventricular (LV) concentric hypertrophy and whether or not these changes are associated with improved diastolic filling. METHODS: An echocardiographic follow-up study was performed in 85 hypertensive patients (systolic blood pressure [SBP] >140 mmHg, diastolic blood pressure [DBP] >90 mmHg) and mild-to-moderate LV hypertrophy (LV mass index related to body surface area [LVMI] 117-150 g/m2 for men and 105-150 g/m2 for women) treated with telmisartan monotherapy 40-80 mg once daily for 1 year. Blood pressure, LVMI, left atrial (LA) volumes, and diastolic function were determined at baseline and after 3, 6, 9, and 12 months of treatment. Blood pressure was also monitored at all visits. Diastolic function was assessed by examination of transmitral inflow and pulmonary vein flow patterns. RESULTS: Telmisartan reduced blood pressure; after 12 months, the mean+/-S.D. SBP and DBP were reduced from 144+/-10 to 126+/-8 mmHg (p<0.001) and from 98+/-8 to 86+/-7 mmHg (p<0.001), respectively. The LVMI was decreased from 119+/-7 to 109+/-3 g/m2 (p<0.001) after 12 months' telmisartan treatment. All patients had diastolic dysfunction at baseline. After 12 months' telmisartan treatment, a normal pattern of transmitral inflow was present in 21% of patients. The regression of LV hypertrophy observed after 12 months was associated with increased peak early diastolic velocity/peak late diastolic velocity ratio from 0.60+/-0.18 to 0.83+/-0.20 (p<0.001), shortened isovolumic relaxation time (IVRT) from 110+/-13 to 105+/-13 ms (p<0.001), and decreased deceleration time from 229+/-30 to 215+/-28 ms (p=0.002). Univariate analysis showed that shortened IVRT was related to a reduction in the LVMI and LA maximal and minimal volumes. In the multivariate analysis, the reduction in LVMI and the reduction in LA maximal and minimal volumes were independently associated with IVRT reduction. CONCLUSIONS: Telmisartan 40-80 mg is effective in LV hypertrophy regression in hypertensive patients. The reduction in LVMI due to telmisartan monotherapy was associated with a significant improvement of diastolic filling parameters and with a significant reduction of LA volumes.     

'Association of platelet function in hypertensive patients with left ventricular hypertrophy'

The present study has used electron microscopic techniques to rapidly detect the success or failure of bone marrow transplantation in three patients with the Chediak-Higashi Syndrome (CHS). The most rapid procedure was the whole mount technique to determine the presence or absence of dense bodies, which are inherently electron-opaque, serotonin-containing storage organelles in platelets. Dense bodies were present in normal numbers in platelets from two patients with successful transplantation and absent in thrombocytes from another patient in whom the transplant had failed.     

Impact of type 2 diabetes on left ventricular geometry and diastolic function in hypertensive patients with chronic kidney disease

Left ventricular hypertrophy (LVH) and diastolic dysfunction are very common in patients with chronic kidney disease (CKD). Aim of this study was to evaluate the impact of type 2 diabetes on LV geometry and diastolic function in hypertensive patients with CKD. We enrolled 288 Caucasian subjects with hypertension and CKD; of them, 112 had diabetes. Patients with cardiovascular (CV) diseases, glomerular filtration rate (GFR) >60?ml?min(-1) per 1.73?m(2), dialysis treatment and other major non-CV diseases were excluded. All patients underwent routine biochemical analyses and echocardiographic examination with tissue Doppler imaging (TDI). Patients with diabetes had significantly higher LV wall thicknesses (P=0.0001), relative wall thickness (RWT) (P=0.0001) and left atrium volume index (P=0.03), when compared with patients without diabetes. Further, diabetic patients had very high prevalence of concentric LVH. Em, evaluated by TDI, was significantly lower in patients with diabetes (P=0.005). However, the difference lost statistical significance after correction by analysis of covariance for RWT. Multiple stepwise linear regression analysis showed that the variables independently associated with Em were: age (β 0.364; P=0.0001), GFR (beta 0.101; P=0.019), and the presence of diabetes (β 0.166; P=0.002). Our study showed that in hypertensive patients with CKD the presence of diabetes is associated with increased LV-wall thicknesses and concentric geometry; further, diabetes together with renal function (GFR) is associated with worse diastolic function, independently of potential confounders, such as age, gender, body mass index and blood pressure.     

胰岛素样生长因子结合蛋白-1降低与2型糖尿病左心室肥厚相关

目的　探讨 2型糖尿病患者左心室肥厚的主要相关因素 ,以及胰岛素样生长因子 (IGF)及其结合蛋白(IGFBP)与左心室肥厚的关系。方法　对 78例 35～ 75岁的非胰岛素治疗的 2型糖尿病无合并冠心病患者 [男 4 0例 ,女38例 ,平均年龄 (5 7 8± 10 5 )岁 ]进行心脏B超扫描 ,检测空腹血清IGF 1、IGF 2、IGFBP 1、IGFBP 3、总胆固醇、甘油三酯、高密度脂蛋白、低密度脂蛋白、apoAl、apoB10 0 、空腹和餐后2h胰岛素 (Ins)、C肽 (C P)水平 ,以及血、尿α1和 β2 MG水平等。结果　 32 0 5 % (2 5 / 78)的观察对象IVS或LVPW≥12mm。与正常组 (LVPW和IVS <12mm )相比 ,LVH组(LVPW或IVS≥ 12mm)IGFBP 1显著降低 [(5 8 2 6± 33 77)ng/mlvs (70 5 2± 4 9 6 9)ng/mlP =0 0 2 6 ],而空腹和餐后2hC肽 ,及血 β2 MG、尿α1 MG明显升高。IGF 1、IGF 2和IGFBP 3在两组间无明显差异。多元逐步回归分析 ,LVPW主要相关因素为血 β2 MG ,和IGFBP 1(R =0 5 4 2 ,P =0 0 0 0 1) ,其中与IGFBP 1负相关 (B =- 0 0 11,t =0 0 4 ) ,与血 β2 MG (B =0 378,t=0 0 0 0 1)正相关 ;IVS主要相关因素为血β2 MG、空腹C肽 (R =0 4 90 ,P =0 0 0 1) ,均为正相关(血 β2 MG ,B =0 377,t =0 0 0 2 ;空腹C肽 ,B =0 772 ,t=0     

Impaired responsiveness of the ventricular sensory receptor in hypertensive patients with left ventricular hypertrophy

We studied the control of forearm vascular resistance (FVR) by cardiopulmonary receptors in seven patients with hypertension and left ventricular hypertrophy (LVH) and in seven normotensive control subjects. Increasing levels of lower body negative pressure (LBNP) (-10 and -40 mm Hg) induced a progressive decrease in central venous pressure (CVP) and an increase in FVR. The changes in these two variables were correlated both in normal subjects and patients with hypertension (slope for normal subjects = -29.9, for patients with hypertension = -40.3, NS). After propranolol, there was a significant reduction in the increase in FVR induced by -40 mm Hg LBNP in normal subjects (+107 +/- 5 vs +129 +/- 15 mm Hg/ml/sec, p less than .05) but not in patients with hypertension. Consequently, the slope of the delta CVP/delta FVR regression was reduced in normal subjects (-20.6, p less than .01) but not in patients with hypertension. In another seven normal subjects and seven patients with hypertension and LVH we assessed the effects of -10 and -40 mm Hg LBNP on left ventricular filling pressure (LVFP). LBNP induced similar changes in CVP, LVFP, and total peripheral resistance both in normal subjects and in patients with hypertension. Propranolol failed to modify the effects of LBNP on CVP and LVFP in both groups and reduced the response of total peripheral resistance to -40 mm Hg LBNP only in normal subjects. Propranolol did not reduce the response of FVR to the cold pressor test and sustained handgrip or the arterial baroreflex response to the injection of phenylephrine and increased neck tissue pressure. Thus, hypertension-induced LVH seems to be associated with a selective impairment of the left ventricular sensory receptors.     

Assessment of left ventricular diastolic function with pioglitazone in type 2 diabetic patients

OBJECTIVES: This study investigated the effect of pioglitazone, an insulin sensitizer, on left ventricular diastolic function in type 2 diabetic patients. METHODS: Various echocardiographic parameters such as left ventricular ejection fraction, transmitral E/A ratio (E/A), deceleration time of E, isovolumetric relaxation time and left ventricular Tei index were measured. A total of 59 patients were enrolled in the ON-group, and the parameters were examined before and after pioglitazone administration (15-30 mg/day) for 6 months, and 9 patients in the OFF-group, and the parameters were examined before and 6 months after cessation of pioglitazone. RESULTS: Average age of subjects was 61.5 years with an age range from 45 to 79 years. Left ventricular ejection fraction and brain natriuretic peptide were not significantly changed both in the ON-group and in the OFF-group. Pioglitazone significantly increased E/A (0.91 +/- 0.23 vs 0.99 +/- 0.24, p < 0.01)and decreased deceleration time of E (233.9 +/- 58.6 vs 209.9 +/- 38.3 msec, p < 0.01), isovolumetric relaxation time(91.5 +/- 13.6 vs 76.0 +/- 12.1 msec, p < 0.01)and left ventricular Tei index (0.38 +/- 0.11 vs 0.35 +/- 0.09, p < 0.01) in the ON-group. On the other hand, E/A (1.08 +/- 0.35 vs 0.88 +/- 0.20, p < 0.01) was significantly decreased and left ventricular Tei index (0.28 +/- 0.11 vs 0.33 +/- 0.11, p < 0.01) was significantly increased in the OFF-group. CONCLUSIONS: Pioglitazone administration improves and cessation worsens left ventricular diastolic function.     

Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass

Aim To characterize the extent to which metabolic syndrome criteriapredict left ventricular (LV) structure and function. Methods and results Metabolic syndrome criteria were assessedin 607 adults with normal LV function. The cohort was groupedaccording to the number of criteria satisfied: (1) Absent (0criteria, n = 110); (2) Pre-Metabolic Syndrome (1–2 criteria,n = 311); and (3) Metabolic Syndrome (3 criteria, n = 186).Echocardiography was used to assess LV structure (LV mass) andsystolic (LVEF, Vs) and diastolic function, by pulse-wave Doppler(E/A ratio) and tissue Doppler imaging (Ve). LV volumes andLVEF were similar between groups. However, LV mass increasedsignificantly and progressively (LVM/Ht^2.7, in g/m^2.7: 34.9± 6.7, 41.0 ± 9.5, 46.3 ± 11.0, P <0.001); LV relaxation decreased progressively (Ve_global', incm/s: 13.5 ± 2.8, 12.1 ± 3.0, 10.5 ± 2.2,P < 0.001) from Absent to Pre-Metabolic Syndrome to MetabolicSyndrome groups, respectively. Multiple variable analyses showedthat diastolic blood pressure, waist circumference, and triglyceridelevels were independent predictors of Ve after adjustment forLV mass. Conclusion Patients with metabolic syndrome have LV diastolicdysfunction independent of LV mass. These functional abnormalitiesmay partially explain the increased cardiovascular morbidityand mortality associated with metabolic syndrome.     

Doppler echocardiographic analysis of left ventricular filling in treated hypertensive patients

Early detection and prevention of cardiac dysfunction is an important goal in the management of hypertensive patients. In this study, Doppler echocardiography was used to evaluate the pattern of left ventricular diastolic filling in 38 subjects: 18 treated hypertensive patients (blood pressure 141 +/- 17/83 +/- 10 mm Hg, mean +/- SD) without other coronary risk factors and 20 risk-free normotensive subjects of similar age (47 +/- 10 and 49 +/- 13 years, respectively). Peak velocity of late left ventricular filling due to the atrial contraction was greater in hypertensive compared with normotensive subjects (69 +/- 14 versus 52 +/- 13 cm/s; p less than 0.001). Peak velocity of late filling was significantly greater in hypertensive versus normotensive subjects in those aged 50 years or younger and those older than age 50 (65 +/- 12 versus 50 +/- 11; p less than 0.01 and 75 +/- 15 versus 56 +/- 15 cm/s; p less than 0.05, respectively). In hypertensive subjects, peak velocity of late filling did not correlate with routine indexes of hypertensive heart disease (including posterior wall thickness and left ventricular mass), systolic and diastolic blood pressure or duration of hypertension. These results indicate that increased velocity of late left ventricular filling may be independent of left ventricular hypertrophy and persist despite effective blood pressure control.     

老年男性高血压合并2型糖尿病对左室结构和舒张功能的影响

目的探讨老年男性高血压患者2型糖尿病对心脏结构和功能的影响及临床意义。方法选择老年男性高血压患者共70例，分为高血压伴糖尿病组及单纯高血压组。采用超声多普勒结合组织多普勒显像（TDI）测定左室结构、左室心肌质量（INM）、左室质量指数（LVMI）、左室舒张功能及左室舒张末压，计算二尖瓣舒张早期最大血流速度（E）与二尖瓣瓣环-侧壁交界处舒张早期速度峰值（Em）的比值（E／Em）。结果①高血压伴糖尿病组患者室间隔（IVS）、左室后壁的厚度（LVPWT）和LVM明显大于单纯高血压组（P〈0．05）。左室内径（LVDd）和LVMI有升高倾向，但无明显差异（P〉0．05）。②高血压伴糖尿病组Em降低，E／Em升高（P〈0．05）。而EF、FS及E峰、A峰、E／A无显著差异（P〉0．05）。③单纯高血压组LVMI与E／Em呈正相关（r=0．336，P〈0．05）。高血压伴糖尿病组LVMI与E／Em、E呈正相关（r=0．74、0．456，P均〈0．05），与Em、Am呈负相关（r=-0．516、-0．42，P均〈0．05）。结论在老年男性高血压患者中2型糖尿病与室壁增厚、LVM增加、左室松弛性受损以及左室舒张末压升高有关，这些对心脏结构和左室舒张功能的有害作用有助于糖尿病患者心血管事件的发生。